Active-ingredient Dossier
Tamoxifen Citrate
Active-ingredient Dossier for Tamoxifen Citrate (selective estrogen receptor modulator). Australian brands, products, PBS listings, PBAC outcomes —…
- Brand: NOLVADEX-D
- Brand: APO-TAMOXIFEN
- Brand: NOLVADEX
- Brand: CHEM
- Therapeutic area: Oncology
What is
Tamoxifen Citrate Tamoxifen Citrate is a selective estrogen receptor modulator.
Australian brands containing
Tamoxifen Citrate — GENOX — NOLVADEX-D — APO-TAMOXIFEN — GENRX — NOLVADEX — TAMOSIN — TAMOXIFEN SANDOZ
Therapeutic areas
Tamoxifen Citrate is registered in oncology, with 10 brands containing this ingredient on the ARTG.
Sponsor landscape
The ingredient is marketed by six sponsors: Arrotex Pharmaceuticals, Southern Cross Pharma, AstraZeneca, Alphapharm, Orion Pharma (AUS), and Sandoz.
PBS and regulatory activity
Two brands containing Tamoxifen Citrate have PBS-listed items, with the latest PBS schedule date being 1 May 2026. The latest PBAC outcome on record is from 1 March 2016, and two brands have PBAC outcomes recorded. No AusPARs have been issued for brands containing this ingredient.